



VRL/SEC/BSE/91

July 26, 2012

Dept. of Corporate Services
The Stock Exchange, Mumbai
25th Floor, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai

Sub. : US patent protection for Venus' POTENTOX

Dear Sir/Madam,

This is to inform you that Venus Remedies Limited has secured its 3rd US patent for its novel antibiotic product – POTENTOX. Granted by the United States Patent and Trademark Office, the patent protects the composition of POTENTOX and the method of treatment.

This US Patent provides an exclusivity period for POTENTOX until May, 2027. In addition to this new patent grant, POTENTOX is protected by a number of other patents from across the Globe including India, Australia, New Zealand, South Korea, South Africa and Ukraine. Potentox is an antibiotic adjuvant entity (AAE); a new drug product effective in case of Hospital Acquired Pneumoniae and Febrile Neutropenia infections, including Quinolones or Aminoglycoside resistance as well.

The Company see this patent grant as a recognition of the capability of not only its own but the Indian pharmaceutical industry as a whole in the field of pharmaceutical research. Potentox US patent has reinstated our capability to bridge the unmet need in the field of antibiotics that would also help in getting the product commercialized in the US markets.

As per the latest reports by Centers of Disease Control and Prevention (CDC), that healthcare-acquired infections cost hospitals in the United States between \$35.7 and \$45 billion annually. It is estimated that the Antibiotic-resistant organisms make up a large part of these infections and result in an estimated 8 million extra days of hospitalization. The portion of excess cost attributable to resistant organisms exceeds \$20 billion annually (Hughes 2011). These costs do not account for antibiotic-resistant infections, which originate outside of the hospital setting.

Infections caused by resistant microorganisms often fail to respond to conventional treatment, resulting in prolonged illness and greater risk of death. Getting a patent grant for POTENTOX from US at such point in time can prove to be all the more significant for Venus Remedies as the drug works synergistically on Multi-drug resistant bacteria that not only halts the development of bacterial resistance but also its spread.

Potentox is the result of years of relentless efforts of scientist at Venus Medicine Research Centre. Venus has done clinical studies on >500 patients, which has indicated approximately 20-30% reduction in the cost of therapy as compared to conventional therapies being used. Besides this,

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India

Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com
www.venusmedicineresearchcentre.com



Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272

Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany



studies conducted in hospitals across India have also shown that the novel antibiotic POTENTOX is suitable for the treatment of Nosocomial Pneumonia and Febrile Neutopenia infections.

The Company has already been marketing POTENTOX successfully in India and few of the emerging markets around the globe. The product is growing with a CAGR of 50% since past 3 years and now Venus is planning to have a pre IND meeting with US FDA for fast track approval of this product. The Company is also open for the strategic tie-ups with the international pharma companies.

Globally, the antibiotics market generated sales of US\$42 billion in 2009, representing 46% of sales of anti-infective agents (which also include antiviral drugs and vaccines) and 5% of the global pharmaceutical market. However, the antibiotics market is maturing; it showed an average annual growth of 4% over the past 5 years, out of this US alone contributes 35% of market share which is US\$12 billion.

Yours faithfully,
for VENUS REMEDIES LIMITED.


Ramanjit Kaur
Assistant Manager
Corporate Communication



VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com



Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany